Dendreon (DNDN) Competition Shadow Looms Larger After ASCO - Jefferies

Article Stock Quotes (1) Comments (0)

Jefferies reiterated their Underperform rating and $5 price target on Dendreon (NASDAQ: DNDN) following strong data from competitors at ASCO.

The firm comments, "Provenge’s outlook takes another severe hit from Zytiga’s striking ~9-mo OS benefit over a higher placebo hurdle in the 302 trial for pre-chemo mCRPC. Given we believe MDV3100 could also match/beat Zytiga on OS, Provenge’s eventual relegation to a niche spot in an otherwise lucrative mkt is looking even likelier."

For an analyst ratings summary and ratings history on Dendreon click here. For more ratings news on Dendreon click here.

Shares of Dendreon closed at $6.76 yesterday, with a 52 week range of $6.46-$42.06.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Citi Raises PT on Micron Technology (MU) to $19
• Deutsche Bank Starts IHS Inc. (IHS) at Hold
• BWS Financial Bumps Price Target on Rambus (RMBS), Keeps 'Hold' Rating

Create E-mail Alert Related Categories

Analyst Comments

Related Entities

Jefferies & Co

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?